dacogen pulbere pentru concentrat pentru solutie perfuzabila 50 mg
janssen-cilag international nv - decitabinum - pulbere pentru concentrat pentru solutie perfuzabila - 50 mg
dacogen
janssen-cilag international n.v. - decitabină - leucemie mieloidă - agenți antineoplazici - tratamentul pacienților adulți cu leucemie mieloidă acută de novo sau secundar nou diagnosticat (aml), conform clasificării organizației mondiale a sănătății (oms), care nu sunt candidați la chimioterapie standard de inducție.
inaqovi
otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leucemie mieloidă - agenți antineoplazici - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.
dacogen
janssen pharmaceutica n.v. - belgia - decitabinum - pulb. pt. conc. pt. sol. perf. - 50mg - antimetaboliti analogi ai bazelor pirimidinice
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
gemcitabin stada 38 mg/ml
stadapharm gmbh - germania - gemcitabinum - conc. pt. sol. perf. - 38mg/ml - antimetaboliti analogi ai bazelor pirimidinice
gemcitabina teva 40 mg/ml
sindan-pharma s.r.l. - romania - gemcitabinum - conc. pt. sol. perf. - 40mg/ml - antimetaboliti analogi ai bazelor pirimidinice
gemcitabina kabi 38 mg/ml
fresenius kabi deutschland gmbh - germania - gemcitabinum - conc. pt. sol. perf. - 38mg/ml - antimetaboliti analogi ai bazelor pirimidinice
gemcitabina sun 10 mg/ml
sun pharmaceutical industries europe b.v. - olanda - gemcitabinum - sol. perf. - 10mg/ml - antimetaboliti analogi ai bazelor pirimidinice
gemcitabina kabi 40 mg/ml
fresenius kabi oncology plc. - marea britanie - gemcitabinum - conc. pt. sol. perf. - 40mg/ml - antimetaboliti analogi ai bazelor pirimidinice